The childhood muscular dystrophies: Making order out of chaos

Seminars in Neurology

Volumn 19, Issue 1, 1999, Pages 9-23

  Tsao, Chang Yong ^a   Mendell, Jerry R ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Congenital muscular dystrophy; Creatine kinase; Dystrophin

Indexed keywords

CORTICOSTEROID; CREATINE KINASE; DEFLAZACORT; DYSTROPHIN; GENE PRODUCT; GLYCOPROTEIN; INTEGRIN; LAMININ; LAMININ RECEPTOR; PREDNISONE; SARCOGLYCAN; UTROPHIN;

BECKER MUSCULAR DYSTROPHY; CATARACT; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CUSHINGOID SYNDROME; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DUCHENNE MUSCULAR DYSTROPHY; GENE THERAPY; GENETICS; GROWTH RETARDATION; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE STRETCHING; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SPLINT; WEIGHT GAIN;

EID: 0033055431     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1040822     Document Type: Review

References (145)

1. Walton JN, Nattrass FJ. On the classification, natural history and treatment of the myopathies. Brain 1954;77:169-231
2. Griggs RC, Mendell JR, Miller RG. Evaluation and treatment of myopathies. Philadelphia: FA Davis, 1996:128-130
3. Koenig M, Hoffman EP, Bertelson EP. et al. Complete cloning of the Duchenne muscular dystrophy cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50:509-517
4. Campbell KP, Kahl SD. Association of dystrophin and an integral membrane glycoprotein. Nature 1989;338:259-262
5. Evasti JM, Ohlendieck K, Kahl SD, et al. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 1990;345:315-319
6. Yoshida M, Ozawa E. Glycoprotein complex anchoring dystrophin to the sarcolemma. J Biochem 1990;108:748-752
7. Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. Cell 1991;66:1121-1131
8. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51:919-928
9. Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 1988;53:219-228
10. Rybakova IN, Amann KJ, Ervasti JM. A new model for the interaction of dystrophin with F-actin. J Cell Bio 1996;135:661-672
11. Rybakova IN, Ervasti JM. Dystrophin-glycoprotein complex is monomeric and stabilizes actin filaments in vitro through a lateral association. J Biol Chem 1997;272:28771-28778
12. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 1991;355:696-702
13. Gee SH, Blacher RW, Douville PJ, et al. Identification and characterization of the dystrophin anchoring site on P-dystroglycan. J Biol Chem 1995;270:27305-27310
14. Jung D, Yang B, Meyer J, Chamberlain JS, Campbell KP. Identification and characterization of the dystrophin anchoring site on P-dystroglycan. J Biol Chem 1995;270:27305-27310
15. Adams ME, Butler MH, Dwyer TM, et al. Two forms of mouse syntrophin, a 58 kd dystrophin-associated protein, differ in primary structure and tissue distribution. Neuron 1993;11:531-540
16. Yang B, Ibraghimov-Beskrovnaya O, Moomaw CR. Heterogeneity of the 59 kDa dystrophin-associated protein revealed by cDNA cloning and expression. J Biol Chem 1995;269:6040-6044
17. Crosbie RH, Heighway J, Venzke DP, Lee JC, Campbell KP. Sarcospan, the 25-kDa transmembrane component of the dystrophin-glycoprotein complex. J Biol Chem 1997;272:31221-31224
18. Ettinger AJ, Feng G, Sanes JR. ε-Sarcoglycan, a broadly expressed homologue of the gene mutated in limb-girdle muscular dystrophy 2D. J Biol Chem 1997;272:32534-32538
19. McNally EM, Ly CT, Kunkel LM. Human ε-Sarcoglycan is highly related to I-sarcoglycan (adhalin), the limb girdle muscular dystrophy 2D gene. FEBS Lett 1998;422:27-32
20. Brenman JE, Chao DS, Xia H, Aldape K, Bredt DS. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 1995;82:743-752
21. Blake DJ, Nawrotzki R, Peters MF, Froehner SC, Davies KE. Isoforms diversity of dystrobrevin, the murine 87-kDa postsynaptic protein. J Biol Chem 1996;271:7802-7810
22. Sadoulet-Puccio HM, Khurana TS, Cohen JB, Kunkel LM. Cloning and characterization of the human homologue of a dystrophin related phosphoprotein found at the Torpedo electric organ post-synaptic membrane. Hum Mol Genet 1996;5: 489-196
23. Sadoulet-Puccio HM, Rajala M, Kunkel LM. Dystrobrevin and dystrophin: An interaction through coiled-coil motifs. Proc Natl Acad Sci US A 1997;94:12413-12418
24. Brooke MH, Fenichel GM, Griggs RC, et al. Clinical investigation in Duchenne dystrophy. 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve 1983;6:91-103
25. Brooke MH, Fenichel GM, Griggs RC, et al. Duchenne muscular dystrophy: Patterns of clinical progression and effects supportive therapy. Neurology 1989;39:475-481
26. Griggs RC, Reeves W, Moxley RT. The heart in Duchenne dystrophy. In: Rowland, LP (ed.) Pathogenesis of Human Muscular Dystrophy. Excerpta Medica, Amsterdam, 1977.
27. Barohn RJ, Levine EJ, Olson JO, Mendell JR. Gastric hypomotility in Duchenne muscular dystrophy. N Engl J Med 1988;319: 15-18
28. Leibowitz D, Dubowitz V. Intellect and behavior in Duchenne muscular dystrophy. Dev Med Child Neurol 1981;23:577-590
29. Hyser CL, Mendell JR. Recent advances in Duchenne and Becker muscular dystrophy. In: Riggs JE (ed). Neurol Clinics: Muscle Disease, Vol 6. Philadelphia: W.B. Saunders, 1988: 429-454
30. Samaha FJ, Quinlan JG. Myalgia and cramps: Dystrophinopathy with wide-ranging laboratory findings. J Child Neurol 1996; 11:21-24
31. Muntoni F, Cau M, Ganau A, et al. Brief report: Deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med 1993;329:921-925
32. Gillard EF, Chamberlain JS, Murphy EG, et al. Molecular and phenotypic analysis of patients with deletions within the deletion-rich region of the Duchenne muscular dystrophy (DMD) gene. Am J Hum Genet 1989;45:507-520
33. Forrest SM, Cross GS, Speer A, et al. Preferential deletion of exons in Duchenne and Becker muscular dystrophies. Nature 1987;329:638-640
34. Hu X, Ray P, Murphy EG, et al. Duplication mutation at the Duchenne muscular dystrophin locus: Its frequency, distribution, origin, and phenotype/genotype correlation. Am J Hum Genet 1990;46:682-595
35. Prior TW. Perspectives and molecular diagnosis of Duchenne and Becker muscular dystrophies. Clin Lab Med 1995;15:927-941
36. Gangopadhyay SB, Sheratt TG, Heckmatt JZ, et al. Dystrophin in frameshift deletion patients with Becker muscular dystrophy. Am J Hum Genet 1992;51:562-570
37. Roberts RG, Gardner RJ. Bobrow M. Searching for the 1 in 2,400,000: A review of dystrophin gene point mutations. Hum Mutat 1994;4:1-11
38. Prior TW, Bartolo C, Pearl DK, et al. Spectrum of small mutations in the dystrophin coding region. Am J Hum Genet 1995;57:22-33
39. Beggs AH, Koenig M, Boyce FM, Kunkel LM. Detection of 98% of DMD/BMD gene deletions in PCR. Hum Genet 1990;86: 45-48
40. Winnard AV, Mendell JR, Prior TW, et al. Frameshift deletions of exons 3-7 and revertant fibers in Duchenne muscular dystrophy: Mechanisms of dystrophin production. Am J Hum Genet 1995;56:158-166
41. Prior TW, Papp AC, Snyder PJ, Mendell JR. Germline mosacism in carriers of Duchenne muscular dystrophy. Muscle Nerve 1992;15:960-963
42. Campbell KP. Three muscular dystrophies: Loss of cytoskeleton-extracellular matrix linkage. Cell 1995;80:675-679
43. Rafael JA, Yoshihide S, Cole NM, et al. Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoforms. Human Mol Genet 1994;3:1725-1733
44. Rafael JA, Cox GA, Corrado K, et al. Forced expression of dystrophin deletion constructs reveals structure-function correlations. J Cell Biol 1996;134:93-102
45. Wells DJ, Wells KE, Asante G, et al. Expression of human fulllength and minidystrophin in transgenic mdx mice: Implications for gene therapy of Duchenne muscular dystrophy. Hum Mol Genet 1995;4:1245-1250
46. Luque ER. Segmental correction of scoliosis with rigid internal fixation: Preliminary report in orthopaedic transections. J Bone Joint Surg 1977;2:136
47. Karpati G, Watters GV. Adverse anaesthetic reactions in Duchenne dystrophy. In: Angelini C, Danielli GA, Fontanari D (eds.) Muscular dystrophy research: Advances and new trends. Excerpta Medica, Amsterdam, 1980
48. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989;320:1592-1597
49. Griggs RC, Moxley RT, Mendell JR, et al. Prednisone in Duchenne dystrophy: A randomized, controlled trial defining the time course and dose response. Arch Neurol 1991;48: 383-388
50. Fenichel GM, Florence JM, Pestronk A, et al. Long term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991;41:1874-1877
51. Fenichel GM, Mendell Jr, Moxley RT, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 1991;48:575-579
52. Brooke MH. A randomized trial of deflazacort and prednisone in Duchenne muscular dystrophy: Effect and toxicity. Neurology 1996;46:A476
53. Angelini C, Pegoraro E, Perini F. A trial with a new steroid in Duchenne muscular dystrophy. In: Angelini C, Danieli GA, Fontanari D (eds.) Dystrophy research. New York: Elsevier, 1991:173-179
54. Mesa LE, Dubrovsky AL, Corderi J, et al. Steroids in Duchenne muscular dystrophy-Deflazacort trial. Neuromusc Dis 1991;4:261-266
55. Moxley RT, Lorenson M, Griggs RC, et al. Decreased breakdown of muscle protein after prednisone therapy in Duchenne dystrophy. J Neurol Sci 1990;98(Suppl):419
56. Kissel JT, Burrow KL, Rammohan KW, Mendell JR, CIDD Study Group. Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. Neurology 1991;41:667-672
57. Burrow KL, Coovert DD, Klein CJ, et al. Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. Neurology 1991;41:661-666
58. Karpati G, Gilbert R, Petrof BJ, Nalbantoglu J. Gene therapy research for Duchenne and Becker muscular dystrophies. Curr Opin Neurol 1997;10:430-435
59. Clemens PR, Kochanek S, Sunada Y, et al. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Therapy 1996;3L965-972
60. Kumar-Singh R, Chamberlain JS. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Human Molecular Genetics 1996;5:913-921
61. Karpati G, Ajdukovic D, Arnold D, et al. Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol 1993;34:8-17
62. Tremblay JP, Malouin F, Roy R, et al. Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant 1993;2:99-112
63. Mendell JR, Kissel JT, Amato AA, et al. Myoblast transfer in the treatment of Duchenne muscular dystrophy. N Engl J Med 1995;333:832-838
64. Karpati G, Carpenter S, Morris GE, et al. Lacalization and quantification of the chromosome 6-encoded dystrophin-related protein in normal and pathological human muscle. J Neuropath Exp Neurol 1993;52:119-128
65. Tinsley JM, Potter AC, Phelps SR, et al. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 1996;384:349-353
66. Bushby K, Beckmann JS. Report on the Thirtieth and Thirty-First ENMC International Workshops on the limb-girdle muscular dystrophies: Proposal for a new nomenclature. Neuromusc Disord 1995;5:337-343
67. Bushby KMD. Diagnostic criteria for the limb-girdle muscular dystrophy: Report of the ENMC consortium on limb-girdle dystrophies. Neuromusc Disord 1995;5:71-74
68. Liu J, Aoki M, Illa I, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nature Genet 1998;20:31-36
69. Bashir R, Britton S, Strachan T, et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nature Genet 1998;20:37-42
70. Gilchrest JM, Pericak-Vance MA, Silverman L, Roses AD. Clinical and genetic investigations in autosomal dominant limb girdle dystrophy. Neurology 1988;37:5-9
71. Speer MC, Yamaoka LH, Gilchrest JM, et al. Confirmation of genetic heterogeneity in limb-girdle muscular dystrophy: Linkage of an autosomal dominant form to chromosome 5q. Am J Hum Genet 1992;50:1211-1217
72. van der Kooi AJ, van Meegen M, Ledderhof TM, et al. Genetic localization of a newly recognized autosomal Dominant limb-girdle muscular dystrophy with cardiac involvement (LGMD1B) to chromosome 1q11-21. Am J Hum Genet 1997;60:891-895
73. van der Kooi AJ, Ledderhof TM, de Voogt WG, et al. A newly recognized autosomal dominant limb girdle muscular dystrophy with cardiac involvement. Ann Neurol 1996;39:636-642
74. Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nature Genet 1998;18:365-368
75. Crosbie RH, Yamada H, Venzke DP, et al. Caveolin-3 is not an integral component of the dystrophin glycoprotein complex. FEBS Letters 1998;427:279-282
76. Fardeau M, Hillaire D, Mignard C, et al. Juvenile limb-girdle muscular dystrophy. Clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain 1996;119:295-308
77. Richard I, Broux O, Allamand V, et al. A novel mechanism leading to muscular dystrophy: Mutations in calpain 3 cause limbgirdle muscular dystrophy type 2A. Cell 1995;81:27-40
78. Fardeau M, Eymard B, Mignard C, et al. Chromosome 15-linked limb-girdle muscular dystrophy: Clinical phenotypes in Reunion Island and French metropolitan communities. Neuromusc Disord 1996;6:447-453
79. Spencer MJ, Tidball JG, Anderson LVB, et al. Absence of calpain 3 in a form of limb-girdle muscular dystrophy (LGMD2A). J Neurol Sci 1997;146:173-178
80. Noguchi S, McNally EM, Ben Othmane K, et al. Mutations in the dystrophin-associated protein γ-sarcoglycan in chromosome 13 muscular dystrophy. Science 1995;270:819-822
81. McNally EM, Passos-Bueno MR, Bonnemann CG, et al. Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation. Am J Hum Genet 1996;59:1040-1047
82. McNally EM, Duggan D, Gorospe R, et al. Mutations that disrupt the carboxyl-terminus of γ-sarcoglycan cause muscular dystrophy. Hum Mol Genet 1996;5:1841-1847
83. Roberds S, Leturcq F, Allamand V, et al. Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell 1994;78:625-633
84. Piccolo F, Roberds SL, Jeanpierre M, et al. Primary adhalinopathy: A common cause of autosomal recessive muscular dystrophy of variable severity. Nature Genet 1995;10:243-245
85. Eymard B, Romero NB, Leturcq F, et al. Primary adhalinopathy (α-sarcoglycanopathy): Clinical, pathologic, and genetic correlation in 20 patients with autosomal recessive muscular dystrophy. Neurology 1997;48:1227-1234
86. Carrié JA, Piccolo F, Leturcq F, et al. Mutational diversity and hot spots in the α-sarcoglycan gene in autosomal recessive muscular dystrophy (LGMD2D). J Med Genet 1997;34:470-475
87. Fadic R, Sunada Y, Waclawik AJ, et al. Deficiency of a dystrophin-associated glycoprotein (adhalin) in a patient with muscular dystrophy and cardiomyopathy. N Engl J Med 1996;334:362-366
88. McNally EM, Bonnemann CG, Kunkel LM, Bhattacharya SK. Deficiency of adhalin in a patient with muscular dystrophy and cardiomyopathy (Letter). N Engl J Med 1996;334:1610-1611
89. Bonnemann CG, Modi R, Noguchi S, et al. β-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nature Genet 1995;11:266-273
90. Lim LE, Duclos F, Broux O, et al. β-sarcoglycan: Characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nature Genet 1995;11:257-265
91. Nigro V, de Sa Moreira E, Piluso G, et al. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the δ-sarcoglycan gene. Nature Genet 1996:195-198
92. Barresi R, Confalonieri V, Lanfossi M, et al. Concomitant deficiency of beta-and gammasarcoglycans in 20 α-sarcoglycan (adhalin)-deficient patients: Immunohistochemical analysis and clinical aspects. Acta Neuropathol 1997;94:28-35
93. van der Kooi AJ, de Voogt WG, Earth PG, et al. The heart in limb-girdle muscular dystrophy. Heart 1998;79:73-77
94. Olson TM, Michels VV, Thibodeau SN, et al. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998;280:750-752
95. Nigro V, Okazaki Y, Belsito A, et al. Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet 1997;6:601-607
96. Duggan DJ, Hoffman EP. Autosomal recessive muscular dystrophy and mutations of the sarcoglycan complex. Neuromusc Disord 1996;6:475-482
97. Duggan DJ, Gorospe JR, Fanin M, et al. Mutations in the sarcoglycan genes in patients with myopathy. N Engl J Med 1997;336:618-624
98. Duggan DJ, Manchester D, Stears KP, et al. Mutations in the δ-sarcoglycan gene are a rare cause of autosomal recessive limb-girdle muscular dystrophy (LGMD2). Neurogenetics 1997;1: 49-58
99. Argon Y, Ward S. Caenorhabditis elegans fertilization-defective mutants with abnormal sperm. Genetics 1980;96:413-433
100. Lim LE, Campbell KP. The sarcoglycan complex in limb-girdle muscular dystrophy. Curr Opin Neurol 1998;11:443-452
101. Roberds SL, Ervasti JM, Anderson RD, et al. Disruption of the dystrophin-glycoprotein complex in the cardiomyopathic hamster. J Biol Chem 1993;268:11490-11499
102. Iwata Y, Nanamura H, Mizuno Y, et al. Detective association of dystrophin with sarcolemmal glycoproteins in the cardiomyopathic hamster heart. FEBS Lett 1993;329:227-231
103. Straub V, Duclos F, Venzke DP, et al. Molecular pathogenesis of muscle degeneration in the d-sarcoglycan deficient hamster. Am J Physiol 1998;153:1623-1630
104. Li J, Dressman D, Tsao YP, et al. rAAV vector-mediated sarcoglycan gene transfer in a hamster model for limb girdle muscular dystrophy. Gene Therapy 1999;6:74-82
105. Tome FMS, Evangelista T, Leclerc A, et al. Congenital muscular dystrophy with merosin deficiency. C R Acad Sci Paris 1994;317:351-357
106. Vainzof M, Marie SKN, Reed UC, et al. Deficiency of merosin (laminin M or α2) in congenital muscular dystrophy associated with cerebral white matter alterations Neuropediatrics 1995; 26:293-297
107. Sunada Y, Edgar TS, Lotz BP, et al. Merosin-negative congenital muscular dystrophy associated with extensive brain abnormal-ities. Neurology 1995;45:2084-2089
108. Pini A, Merlini L, Tome FMS, et al. Merosin-negative congenital muscular dystrophy, occipital epilepsy with periodic spasms and focal cortical dysplasia. Report of three Italian cases in two families. Brain Dev 1996;18:316-322
109. Shorer Z, Philpot J, Muntoni F, et al. Peripheral nerve involvement in congenital muscular dystrophy. J Child Neurol 1995; 10:472-475
110. Tsao CY, Mendell JR, Rusin J, Luquette M. Congenital muscular dystrophy with complete laminin α2 deficiency, cortical dysplasia, and cerebral white matter changes in children. J Child Neurol 1998;13:253-256
111. Sewry CA, Naom I, D'lessandro M, et al. Variable clinical phenotype in merosin-deficient congenital muscular dystrophy associated with differential immunolabeling of two fragments of the laminin α2 chain. Neuromusc Disord 1997;7:169-175
112. Sewry CA, Philpot J, Sorokin LM, et al. Diagnosis of merosin (laminin 2) deficient congenital muscular dystrophy by skin biopsy. Lancet 1996;347:582-584
113. Hillaire D, Leclerc A, Faure S, et al. Localization of merosin-negative congenital muscular dystrophy to chromosome 6q2 by homozygosity mapping. Hum Mol Genet 1994;3:1657-1661
114. Helbling-Leclerc A, Zhang X, Topaloglu H, et al. Mutations in the laminin α2-chain gene (LAMA) cause merosin-deficient congenital muscular dystrophy. Nature Genet 1995;11:216-218
115. Nissenen M, Helbling-Leclerc A, Zhang X, et al. Substitution of a conserved cysteine 996 in a cysteine rich motif of the laminin alpha2-chain in congenital muscular dystrophy with partial deficiency of the protein. Am J Hum Genet 1996;58:1177-1184
116. Guicheney P, Vignier N, Helbling-Leclerc A, et al. Genetics of laminin α2 chain (or merosin) deficient congenital muscular dystrophy: From identification of mutations to prenatal diagnosis. Neuromusc Disord 1997;7:180-186
117. Allamand V, Sunada Y, Salih MAM, et al. Mild congenital muscular dystrophy in two patients with an internally deleted laminin α2-chain. Hum Mol Genet 1997;6:747-752
118. Mendell JT, Panicker SG, Tsao C-Y, et al. Novel compound heterozygous laminin laminin α2 chain (LAMA2) gene mutations (exon 4 nonsense and exon 54 frameshift) in congenital muscular dystrophy. Hum Mutation in brief #159 1997 (on line).
119. Sunada Y, Bernier SM, Kozak CA, et al. Deficiency of merosin in dystrophic dy mice and genetic linkage of laminin M chain gene to dy locus. J Biol Chem 1994;269:13729-13732
120. Xu H, Wu X-R, Wewer UM, Engvall E. Murine muscular dystrophy caused by a mutation in the laminin α2 (LAMA2) gene. Nat Genet 1994;8:297-302
121. 2j mice. Hum Mol Genet 1995;4:1055-1061
122. Lafrenie RM, Yamada KM. Integrin-dependent signal transduction. J Cell Biochem 1996;61:543-553
123. Meredith JE, Jr, Schwartz MA. Integrins, adhesion and apoptosis. Trends Cell Biol 1997;7:477-478
124. Yao CC, Ziober BL, Sutherland AE, et al. Laminins promote the locomotion of skeletal myoblasts via the alpha 7 integrin receptor. J Cell Sci 1996;109:3139-3150
125. Hayashi YK, Chou F-L, Engvall E, et al. Mutation in the integrin α7 gene cause congenital myopathy. Nature Genet 1998;19:94-97
126. Mayer U, et al. Absence of integrin alpha 7 causes a novel form of muscular dystrophy. Nature Genet 1997;17: 318-323
127. Fukuyama Y, Kawazura M, Haruna H. A peculiar form of congenital progressive muscular dystrophy. Report of 15 cases. Paediatr Univ Tokyo 1960;4:5-8
128. Fukuyama U, Osawa M, Suzuki H. Congenital progressive muscular dystrophy of Fukuyama type-clinical, genetic, and pathologic considerations. Brain Dev 1981;13:1-29
129. Santavuori P, Leisti J, Kruus S. Muscle, eye and brain disease. A new syndrome. Neuropediatrics 1977;8(Suppl 8):553
130. Warburg M. The heterogeneity of microphthalmia in the mentally retarded. Birth Defects 1971;7:136-154
131. Dambska M, Wisniewski K, Sher J, Solish G. Cerebro-oculomuscular syndrome: A variant of Fukuyama congenital cerebromuscular dystrophy Clin Neuropathol 1982;1:93-98
132. Korinthenberg R, Pal D, Schlake W, Klein J. Congenital muscular dystrophy, brain malformations and ocular problems (muscle, eye, and brain disease) in two German families. Eur J Pediatr 1984;142:64-68
133. Towfighi J, Sassani JW, Suzuki K, Ladda RI. Cerebro-oculardysplasia-muscular dystrophy (COM-MD). Acta Neuropathol 1984;65:110-123
134. Williams RS, Swisher CN, Jennings M, et al. Cerebro-ocular dysgenesis (Walker-Warburg syndrome): Neuropathologic and etiologic analysis. Neurology 1984;34:1531-1541
135. Haltia M, Leivo I, Somer H, et al. Muscle-eye-brain disease: A neuropathological study. Ann Neurol 1997;41:173-180
136. Hayashi Y, Engvall E, Arikawa-Hirasawa E, et al. Abnormal localization of laminin subunits in muscular dystrophies. J Neurol Sci 1993;119:53-64
137. Kobayashi K, Nakahori Y, Miyake M, et al. An ancient retro-transposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998;394:388-392
138. Eberhart DE, Curran T. Yayoi era mutation disrupts brain and muscle. Nature Med 1998;4:1002-1003
139. Toda T, Segawa M, Nomura Y, et al. Localization of a gene for Fukuyama type congenital muscular dystrophy to chromosome 9q31-33. Nature Genet 1993;5:283-286
140. Ranta S, Pihko H, Santavuori P, et al. Muscle-eye-brain disease and Fukuyama type congenital muscular dystrophy are not allelic. Neuromusc Disord 1995;5:221-225
141. Toda T, Yoshioka M, Nakahori Y, et al. Genetic identity of Fukuyama-type congenital muscular dystrophy and Walker-Warburg syndrome. Ann Neurol 1995;37:99-100
142. Dobyns W, Pagon R, Armstrong D, et al. Diagnostic criteria for Walker-Warburg syndrome. Am J Med Genet 1989;32: 195-210
143. Wever UM, Durkin ME, Shang X, et al. Laminin α2 chain and adhalin deficiency in the skeletal muscle of Walker-Warburg syndrome (cerebro-ocular dysplasia muscular dystrophy) Neurology 1995;45:2099-2111
144. Voit T, Sewry CA, Meyer K, et al. Preserved merosin M-chain (or laminin-α2) expression in skeletal muscle distinguishes Walker-Warburg syndrome from Fukuyama muscular dystrophy and merosin-deficient congenital muscular dystrophy. Neuropediatrics 1995;26:148-155
145. Weller T, Greenberg CR, Zelinski T, et al. A gene for autosomal recessive limb-girdle muscular dystrophy in Manitoba Hutterites maps to chromosome region 9q31033: Evidence for another limb-girdle muscular dystrophy locus. Am J Hum Genet 1998;63:140-147